Lindsey Shapiro, PhD, science writer —

Soleno Therapeutics has announced that its diazoxide choline controlled release (DCCR) tablets will be evaluated in a clinical trial for people with early-phase Prader-Willi Syndrome (PWS), which will be funded by Running for Research – Prader-Willi Syndrome, an ongoing fundraiser to benefit PWS research operated by the University…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TNX-2900, Tonix Pharmaceuticals’ oxytocin therapy for Prader-Willi syndrome (PWS). Orphan designation is intended to speed the development of potential therapies for rare diseases, or those affecting fewer than 200,000 people in the U.S. The status…

A case of acute kidney injury in a woman with Prader-Willi syndrome (PWS) and intellectual disability was attributed in a recent report to the use of multiple medications. The case shed lights on how vulnerable people with an intellectual disability are to being over-medicated, with the complications…

Several characteristics during pregnancy and immediately after birth — such as maternal age, pregnancy complications, low birth size, reduced muscle tone, and infant feeding difficulties — may distinguish a newborn with Prader-Willi Syndrome (PWS) from healthy babies early in life, a study showed. “By providing an overview of…

Researchers have documented the first case of a rare condition characterized by neurocognitive regression and epileptic seizures during sleep in a child with Prader-Willi syndrome (PWS). Their case report, “Electrical status epilepticus during sleep in a child with Prader-Willi syndrome: a case report,” was published in…